Cocrystal PharmaCOCP -0.96%25 PS Ratio is 64.38 as of Jun. 29, 2026, which is 85% above its 10-year median of 34.77. GuruFocus rates COCP with a GF Score™ of 25/100. The stock has 3 warning signs investors should review. Among 935 Biotechnology companies, Cocrystal Pharma ranks worse than 81.5% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Cocrystal Pharma's share price is $1.03.
Cocrystal Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.02. Hence, Cocrystal Pharma's PS Ratio for today is 64.38.
The historical rank and industry rank for Cocrystal Pharma's PS Ratio or its related term are showing as below:
COCP'
s PS Ratio Range Over the Past 10 Years
Min: 2.03 Med: 34.77 Max: 15600.16
Current: 64.39
During the past 13 years, Cocrystal Pharma's highest PS Ratio was 15600.16. The lowest was 2.03. And the median was 34.77.
COCP's PS Ratio is ranked worse than 81.5% of 935
companies
in the Biotechnology industry
Industry Median: 9.29
vs COCP: 64.39
During the past 13 years, Cocrystal Pharma's highest 3-Year average Revenue per Share Growth Rate was -93.20% per year. The lowest was -93.20% per year. And the median was -93.20% per year.
Back to Basics: PS Ratio
Cocrystal Pharma (NAS:COCP) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Cocrystal Pharma PS Ratio Related Terms
Cocrystal Pharma PS Ratio Historical Data
* Premium members only.
The historical data trend for Cocrystal Pharma's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Cocrystal Pharma's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cocrystal Pharma PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cocrystal Pharma's PS Ratio distribution charts can be found below:
* The bar in red indicates where Cocrystal Pharma's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Cocrystal Pharma's Share Price of today is $1.03. Cocrystal Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.02.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Cocrystal Pharma (COCP) has a PS Ratio of 64.38 as of Jun. 29, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Cocrystal Pharma and its competitors. This is 85% above median its historical median of 34.77. Over the past decade, Cocrystal Pharma's PS Ratio has ranged from 2.03 to 15,600.16. According to the industry distribution chart, Cocrystal Pharma ranks #762 out of 935 companies in the Biotechnology industry, placing it in the top 81.5%.
Is Cocrystal Pharma's PS Ratio too high?
Cocrystal Pharma's current PS Ratio of 64.38 is 85% above median its 10-year median of 34.77. Over the past 10 years, this metric has ranged from a low of 2.03 to a high of 15,600.16. The Biotechnology industry median PS Ratio is 9.29. Cocrystal Pharma's value of 64.38 is 593% above this industry median. Based on the distribution chart, Cocrystal Pharma ranks #762 out of 935 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cocrystal Pharma has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Cocrystal Pharma's PS Ratio compare to HOOK and LNAI?
According to the Biotechnology industry distribution chart, Cocrystal Pharma ranks #762 out of 935 companies for PS Ratio. This places Cocrystal Pharma in the lower half of its industry. The industry median PS Ratio is 9.29. Cocrystal Pharma's value of 64.38 is 593% above this benchmark. Historically, Cocrystal Pharma's own PS Ratio has ranged from 2.03 to 15,600.16 over the past decade. While the company's 10-year median is 34.77 vs. the industry median of 9.29, Cocrystal Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.29, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cocrystal Pharma's current PS Ratio of 64.38 is 593% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Cocrystal Pharma and its competitors. For the Biotechnology industry, the median PS Ratio is 9.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cocrystal Pharma's current PS Ratio is 64.38, which is 85% above median its own 10-year median of 34.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cocrystal Pharma stock overvalued right now?
Cocrystal Pharma (COCP) has a current PS Ratio of 64.38. The current PS Ratio is 64.38, which is 85% above median its 10-year median of 34.77 and 593% above the Biotechnology industry median of 9.29. Cocrystal Pharma's overall GF Score™ is 25/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Cocrystal Pharma (COCP), the current PS Ratio is 64.38 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.
25GF Score
Get the complete analysis for COCP
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COCP has been successfully added to your 
